A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

Inclusion Criteria for All Participants:

• Participants must have stable renal function as defined by less than 20% change inestimated glomerular filtration rate (eGFR) between the first and second screeningsample with the first screening visit occurring within 28 days prior to dosing onDay 1 and the second screening visit occurring no more than 14 days apart, but atleast 72 hours apart from the first.

• Body mass index (BMI) within the range 18.5 to 40.0 kg/m^2 at screening.

• Female and Male participants must consent to follow contraception requirements

• Capability of giving signed informed consent form

Inclusion Criteria: Additional Criteria Specific to Healthy Participants:

• Must be in the opinion of the investigator, be in good health based upon medicalhistory, vital signs, physical examination, and screening laboratory evaluations

• Must have normal renal function as defined by eGFR ≥ 90 mL/min/1.73m^2 based on theModification of Diet in Renal Disease (MDRD) equation determined from the mean oftwo measurements of serum creatinine at screening.

Inclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment

• Participants must, in the opinion of the investigator, be sufficiently healthy forstudy participation based on medical history, physical examination, vital signs, andscreening laboratory evaluations

• Participants with RI must have chronic moderate or severe RI and be clinicallystable per investigator assessment for at least 3 months prior to screening

• Moderate RI as defined by eGFR level 30-59 mL/min/1.73m^2 based on the MDRDequation, or

• Severe RI as defined by eGFR level 15-29mL/min/1.73m^2 based on the MDRD equation

Exclusion Criteria: Criteria for All Participants

• Any clinically significant medical condition or psychiatric condition that mayinterfere with study intervention

• Participants with uncontrolled hypertension, asthma, and/or diabetes (Type I or II).

• Participants with diabetes

• Participants with any active malignancy

• Participants with vasculitis or conditions associated with vasculitis.

• Participants who have undergone major surgery within 12 months of screening

• Participants with unstable cardiac functions, abnormality, or clinically significantheart failure

• Participants with infection of HIV, HAV, HBV, HCV, HDV, or HEV

• Participants with signs of active infection

• History of bone marrow or solid organ transplantation

• Participants with end-stage renal disease or nephrotic syndrome as defined by:participants requiring hemodialysis or peritoneal dialysis, participants who haveundergone or are listed for transplant, or participants who have chronic kidneydisease with nephrotic syndrome

• Participants with active nephritis

• Participants with clinically significant liver disease

• History of drug or alcohol abuse

• Unwillingness or inability to follow procedures outlined in protocol

Exclusion Criteria: Additional Criteria Specific to Healthy Participants

• Use of any prescription medications or over-the-counter medications (with theexception of vitamins and/or hormonal contraceptive medications) including herbalproducts within 30 days prior to D1 of study participation

Exclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment

• Not on stable dose and regimen of any medication(s) (prescription orover-the-counter) that the participants is taking regularly (eg, medications forchronic conditions such as hypertension, high cholesterol, or depression must not bechanged in dose or type for at least 2 weeks prior to study drug administration).Use of other prescription medications or over-the-counter medications that are notfor chronic conditions (with the exception of vitamins and/or hormonal contraceptivemedications) including herbal products within 30 days prior to D1 of studyparticipation